Loading...

QuidelOrtho Corporation

QDELNASDAQ
Healthcare
Medical - Instruments & Supplies
$28.82
$-0.05(-0.17%)

QuidelOrtho Corporation (QDEL) Stock Overview

Explore QuidelOrtho Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 69.9/100

Key Financials

Market Cap1.9B
P/E Ratio-5.85
EPS (TTM)$-5.23
ROE-0.11%
Fundamental Analysis

AI Price Forecasts

1 Week$29.78
1 Month$18.57
3 Months$20.90
1 Year Target$32.91

QDEL Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of QuidelOrtho Corporation (QDEL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $32.91.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -5.85 and a market capitalization of 1.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
-7.17%
7.17%
Profit Growth
$-4.94
20216.83%
EPS Growth
$-4.94
20006.67%
Operating Margin
-3.01%
1509.71%
ROE
-10.82%
20216.83%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$50.00
Average$53.50
High$57.00

Company Profile

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

CEO

Brian J. Blaser

Employees

6,600

Headquarters

9975 Summers Ridge Road, San Diego, CA

Founded

1991

Frequently Asked Questions

;